Grifols, S.A. (BME: GRF)

Market Cap	6.35B
Revenue (ttm)	6.81B
Net Income (ttm)	165.67M
Shares Out	679.63M
EPS (ttm)	0.22
PE Ratio	44.34
Forward PE	12.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	615,490
Open	9.70
Previous Close	9.86
Day's Range	9.52 - 9.87
52-Week Range	6.36 - 15.92
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 23,505
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: GRF

Financial Performance

In 2023, ANE's revenue was 3.98 billion, a decrease of -15.08% compared to the previous year's 4.69 billion. Earnings were 524.00 million, a decrease of -30.96%.